Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


HELP panel to act quickly on Daschle

This article was originally published in The Tan Sheet

Executive Summary

Sen. Ted Kennedy, D-Mass., is moving expeditiously to help President-elect Obama install his team at HHS and begin the health care reform debate. The 111th Congress convenes Jan. 6, and confirmation hearings for Tom Daschle as HHS Secretary will be held Jan. 8 by the Health, Education, Labor and Pensions Committee, which Kennedy chairs. Confirmation should be swift for Daschle, the former Senate Democratic leader, enabling a quick turn to other HHS personnel matters, such as the new commissioner at FDA

You may also be interested in...

Daschle’s Prescription For FDA: Leadership, Policy, Funding And Coordination

Restoring confidence in FDA "as the leading science-based regulatory agency in the world" will be a priority, Health & Human Services Secretary nominee Tom Daschle told a Senate committee

Ready, Set, Guidance: FDA Releases Final Details Ahead Of ASCA Pilot Launch

A trio of newly finalized guidance documents from the US agency dated 25 September explain how the Accreditation Scheme for Conformity Assessment pilot will work, and what biocompatibility and safety standards will apply.

With Preservative-Free Alaway Eye Drops, Bausch Expands OTC Portfolio Of Planned Spin-Off

Approval of Alaway Preservative Free (ketotifen fumarate, 0.035) comes 15 months after FDA submitted a complete response letter to Bausch and the active ingredient developer, Eton Pharmaceuticals. 





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts